Sangamo Regains Full Rights to Hemophilia A Gene Therapy
Sangamo Therapeutics will regain control of giroctocogene fitelparvovec, a hemophilia A gene therapy candidate, after Pfizer terminated their collaboration...
Delcath Systems Secures $16.3M in Funding
Delcath Systems, Inc. secured $16.3 million in funding through the exercise of Series E and E1 warrants, with a...
Kala Bio’s $10.75M Private Placement: A Promising Opportunity?
Kala Bio, a clinical-stage biopharmaceutical company focused on eye diseases, secured approximately $10.75 million in a private placement involving...
Telix Pharma: Noble Registry Update: TLX599-CDX PSMA SPECT Imaging
Telix Pharmaceuticals and the Oncidium foundation announced positive initial results from the NOBLE Registry, a real-world evidence study of...
How Novartis is Using AI for Clinical Trial Feasibility and Site Selection
Novartis is at the forefront of modernizing clinical trial processes by integrating AI to enhance trial feasibility and site...
Beigene Tevibra Approved in US for Gastric Cancer Treatment
The FDA approved BeiGene‘s TEVIMBRA (tislelizumab-jsgr), combined with chemotherapy, for first-line treatment of advanced HER2-negative gastric or gastroesophageal junction...
Takeda Hyqvia 10% Injection Approved in Japan for Immunodeficiency
Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare for HYQVIA, a facilitated subcutaneous immunoglobulin...
Psyence Biomed Closes $2M Private Placement
Psyence Biomedical Ltd., a Nasdaq-listed biotechnology company (Nasdaq: PBM), recently finalized a private placement, raising approximately $2 million before...
Vor Bio Announces $55.6M Private Placement
Vor Bio, a clinical-stage cell and genome engineering company, has secured approximately $55.6 million in gross proceeds through a...
Ikena Oncology and Inmagene Merger Announcement
Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement. The combined company will focus on developing...